Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force

Jordana E. Hoppe, Jacquelyn Sjoberg, Gina Hong, Katie Poch, Edith T. Zemanick, Stephanie Thee, Claire Edmondson, Dhiren Patel, Meghana Sathe, Drucy Borowitz, Melissa S. Putman, Noah Lechtzin, Kristin A. Riekert, Melissa Basile, Christopher H. Goss, Mary Elizabeth Jarosz, Margaret Rosenfeld

Research output: Contribution to journalReview articlepeer-review

Abstract

The COVID-19 pandemic necessitated a rapid shift in clinical research to perform virtual visits and remote endpoint assessments, providing a key opportunity to optimize the use of remote endpoints for clinical trials in cystic fibrosis. The use of remote endpoints could allow more diverse participation in clinical trials while minimizing participant burden but must be robustly evaluated to ensure adequate performance and feasibility. In response, the Cystic Fibrosis Foundation convened the Remote Endpoint Task Force (Supplemental Table 1), a multidisciplinary group of CF researchers with remote endpoint expertise and community members tasked to better understand the current and future use of remote endpoints for clinical research. Here, we describe the current use of remote endpoints in CF clinical research, address key unanswered questions regarding their use and feasibility, and discuss the next steps to determine clinical trial readiness.

Original languageEnglish (US)
Pages (from-to)725-733
Number of pages9
JournalJournal of Cystic Fibrosis
Volume23
Issue number4
DOIs
StatePublished - Jul 2024

Keywords

  • Clinical trials
  • Cystic fibrosis
  • Home
  • Remote monitoring

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force'. Together they form a unique fingerprint.

Cite this